ABBV — AbbVie Inc. catalysts
Next verified catalyst
2026-07-01 — Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ N · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07 (month) in 9d
ESTIMATED |
READOUT
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treate
Phase 2 · Non-small Cell Lung Cancer |
ABBV AbbVie Inc. | Telisotuzumab vedotin |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-07 (month) in 9d
ESTIMATED |
READOUT
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Phase 3 · Open-Angle Glaucoma, Ocular Hypertension |
ABBV AbbVie Inc. | Bimatoprost SR |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-07 (month) in 9d
ESTIMATED |
READOUT
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitin
Phase 3 · Rheumatoid Arthritis |
ABBV AbbVie Inc. | Upadacitinib, Adalimumab, Upadacitinib M |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-07 (month) in 9d
ESTIMATED |
READOUT
A Study to Assess Adverse Events and Change in Disease Activity in Participants
Phase 2 · Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer |
ABBV AbbVie Inc. | Mirvetuximab Soravtansine |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexameth
Phase 3 · Multiple Myeloma |
ABBV AbbVie Inc. | Pomalidomide, Dexamethasone, Venetoclax |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants W
Phase 2 · Neovascular Age-Related Macular Degeneration (nAMD) |
ABBV AbbVie Inc. | Ranibizumab, ABBV-RGX-314 Dose 1, ABBV-R |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Der
Phase 3 · Atopic Dermatitis |
ABBV AbbVie Inc. | Upadacitinib 15mg Dose, Dupilumab 300mg |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08 (month) in 1mo
ESTIMATED |
READOUT
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear
Phase 3 · Dry Eye Disease |
ABBV AbbVie Inc. | ABBV-444, REFRESH OPTIVE UD |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-19 in 2mo
CONFIRMED |
APPROVED
RINVOQ LQ
|
ABBV AbbVie Inc. | RINVOQ LQ |
openFDA (drugsfda) ↗
✓ Source-checked 2026-06-22
Actual/recorded date
|
| 2026-09 (month) in 2mo
ESTIMATED |
READOUT
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug M
Phase 3 · Juvenile Psoriatic Arthritis |
ABBV AbbVie Inc. | Adalimumab, Risankizumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10 (month) in 3mo
ESTIMATED |
READOUT
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · AMD, nAMD |
ABBV AbbVie Inc. | ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax
Phase 2 · Chronic Lymphocytic Leukemia (CLL) |
ABBV AbbVie Inc. | Venetoclax, Obinutuzumab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Fo
Phase 2 · High Grade Ovarian Cancer, Primary Peritoneal Cancer |
ABBV AbbVie Inc. | Mirvetuximab soravtansine, Carboplatin |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraveno
Phase 2 · Hepatocellular Carcinoma |
ABBV AbbVie Inc. | Budigalimab, Livmoniplimab, Lenvatinib, |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-11 (month) in 4mo
ESTIMATED |
READOUT
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932
Phase 2 · Generalized Anxiety Disorder (GAD) |
ABBV AbbVie Inc. | ABBV-932, Antidepressant Therapy (ADT) |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
Past
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-12 10d ago
CONFIRMED |
APPROVED
SKYRIZI
|
ABBV AbbVie Inc. | SKYRIZI |
openFDA (drugsfda) ↗
✓ Source-checked 2026-06-22
Actual/recorded date
|
| 2026-06-12 10d ago
CONFIRMED |
APPROVED
SKYRIZI
|
ABBV AbbVie Inc. | SKYRIZI |
openFDA (drugsfda) ↗
✓ Source-checked 2026-06-22
Actual/recorded date
|